Literature DB >> 7889597

Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP).

V Guyard-Dangremont1, L Lagrost, P Gambert, C Lallemant.   

Abstract

The present report describes the first competitive enzyme-linked immunosorbent assay (ELISA) for the cholesteryl ester transfer protein (CETP), an enzyme playing an important role in lipoprotein metabolism. This assay was developed with well-characterized TP1 anti-CETP monoclonal antibodies. The sensitivity of the ELISA assay was comparable with the sensitivity of the previously described radioimmunoassays since 1 ng of CETP per microwell of the immunoplate could be detected. Intra- and inter-assay coefficients of variation were 4% and 6%, respectively. This enzyme immunoassay provides a specific, sensitive and reproducible method for measuring CETP concentrations in various biological samples. Within normolipidemic subjects, the mean (+/- S.D.) of the plasma CETP concentration was 2.77 (+/- 0.59) micrograms/ml with a range of 1.87 to 4.23 micrograms/ml. When plasmas were supplemented with fatty acid-free albumin, the positive correlation observed between plasma CETP mass and CETP activity was improved, suggesting that plasma non-esterified fatty acids could play a role in modulating the activity of the cholesteryl ester transfer protein. When applied to the study of the binding of CETP to lipoprotein substrates, the enzyme immunoassay revealed that the experimental protocol used to separate lipoprotein fractions can have a great influence on the plasma distribution of CETP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889597     DOI: 10.1016/0009-8981(94)90199-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.

Authors:  Xavier Pillois; Thomas Gautier; Benjamin Bouillet; Jean-Paul Pais de Barros; Aline Jeannin; Bruno Vergès; Jacques Bonnet; Laurent Lagrost
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

2.  Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice.

Authors:  Thomas Gautier; Willeke de Haan; Jacques Grober; Dan Ye; Matthias J Bahr; Thierry Claudel; Niels Nijstad; Theo J C Van Berkel; Louis M Havekes; Michael P Manns; Stefan M Willems; Pancras C W Hogendoorn; Laurent Lagrost; Folkert Kuipers; Miranda Van Eck; Patrick C N Rensen; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2013-04-25       Impact factor: 5.922

3.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

4.  Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.

Authors:  Jean-Paul Pais de Barros; Aurélia Boualam; Thomas Gautier; Laure Dumont; Bruno Vergès; David Masson; Laurent Lagrost
Journal:  J Lipid Res       Date:  2009-05-05       Impact factor: 5.922

5.  Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

Authors:  Bruno Vergès; Emmanuel Florentin; Sabine Baillot-Rudoni; Jean-Michel Petit; Marie Claude Brindisi; Jean-Paul Pais de Barros; Laurent Lagrost; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2009-01-22       Impact factor: 5.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.